KFSHRC Successfully Treats Severe Case of "Xanthoma" After 26 Years of Suffering
June 02, 2024 11:31 ET
|
King Faisal Specialist Hospital & Research Centre
KFSHRC Successfully Treats Severe Case of "Xanthoma" After 26 Years of Suffering
Flash News: OKX Now Supports Wormhole Protocol's W Token on Ethereum Mainnet
June 02, 2024 11:27 ET
|
OKX
DUBAI, United Arab Emirates, June 02, 2024 (GLOBE NEWSWIRE) -- OKX, a leading crypto exchange and Web3 technology company, has issued updates for June 2, 2024. OKX Now Supports Wormhole Protocol's...
Seer Technology Access Center Provides Unprecedented Scale and Depth of Coverage for PrognomiQ’s Early Cancer Detection Study
June 02, 2024 10:55 ET
|
Seer, Inc.
REDWOOD CITY, Calif., June 02, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, announced today that...
Nanobiotix Announces New Data Showing Disease Control and Tumor Response in Patients Treated With RT-Activated NBTXR3 Followed By anti-PD-1 For 2l+ R/M HNSCC Naïve or Resistant to Prior anti-PD-1 Therapy
June 02, 2024 10:00 ET
|
Nanobiotix S.A.
Data show favorable safety and feasibility in 68 heavily pre-treated patients with R/M-HNSCC (Intention-to-Treat population; “ITT”) who received RT-activated NBTXR3 followed by anti-PD-1 as a...
Precede Biosciences Presents New Data at ASCO 2024 Demonstrating Accurate HER2 Status Detection Across Multiple Cancers and the Ability to Quantify ER Pathway Activation in Breast Cancer from a Simple Blood Test
June 02, 2024 10:00 ET
|
Precede Biosciences, Inc.
HER2 status was accurately assessed in 172 patients with advanced breast, gastroesophageal, and ovarian cancersER status was accurately assessed and the level of ER pathway activation quantified in 87...
ALX Oncology Presents First Evorpacept Combination Data with an Antibody-Drug Conjugate from Phase 1 ASPEN-07 Clinical Trial in Patients with Advanced Bladder Cancer
June 02, 2024 10:00 ET
|
ALX Oncology
Evorpacept in combination with PADCEV®, an approved antibody-drug conjugate (“ADC”), demonstrated promising activity and was generally well toleratedCompany to host conference call and webcast with...
BIIB INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Biogen, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
June 02, 2024 09:51 ET
|
Robbins Geller Rudman & Dowd LLP
SAN DIEGO, June 02, 2024 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Biogen Inc. (NASDAQ: BIIB) securities between February 3, 2022 and...
Celldex Therapeutics Presents Data Demonstrating Profound Improvements in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2024
June 02, 2024 09:01 ET
|
Celldex Therapeutics, Inc.
- Clinically meaningful and statistically significant improvements across multiple angioedema measurements and barzolvolimab dose groups -- Sustained activity with rapid onset within 2 weeks -- Data...
ImPact Biotech Presents Additional Interim Data from ENLIGHTED Study of Padeliporfin VTP in Low Grade Upper Tract Urothelial Cancer
June 02, 2024 09:00 ET
|
ImPact Biotech
Promising response rate in patients with low-grade upper tract urothelial cancer (UTUC); complete response (CR) observed in 77% (10/13) of patients who completed the Induction Treatment...
NVIDIA Enables Real-Time Healthcare, Industrial and Scientific AI Applications at the Edge With Enterprise Software Support for NVIDIA IGX With Holoscan
June 02, 2024 08:56 ET
|
NVIDIA
TAIPEI, Taiwan, June 02, 2024 (GLOBE NEWSWIRE) -- COMPUTEX -- To address the increasing need for real-time AI computing at the industrial edge, NVIDIA today announced the general software...
- June 02, 2024 11:31 ET KFSHRC Successfully Treats Severe Case of "Xanthoma" After 26 Years of Suffering
- June 02, 2024 10:00 ET Nanobiotix Announces New Data Showing Disease Control and Tumor Response in Patients Treated With RT-Activated NBTXR3 Followed By anti-PD-1 For 2l+ R/M HNSCC Naïve or Resistant to Prior anti-PD-1 Therapy